Friday, December 14, 2012
Bayer seeks FDA approval for cancer drug radium-223
Bayer seeks FDA approval for cancer drug radium-223: FRANKFURT (Reuters) - German drugmaker Bayer said on Friday it requested approval from U.S. regulators for an experimental prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment